Results 201 to 210 of about 30,695 (301)

Which Small-Sample Correction Should be Used When Analyzing Stepped-Wedge Designs With Time-Varying Treatment Effects? [PDF]

Stat Med
Ouyang Y, Taljaard M, Hughes JP, Li F.
europepmc   +1 more source

From prediction to intervention: Causal artificial intelligence as the missing link in precision therapeutics

Precision Medical Sciences, EarlyView.
Predictive multiomics artificial intelligence (AI) identifies risk but does not indicate which intervention will change a patient's outcome; causal AI, anchored in biological mechanism, bridges this gap to enable individualized treatment decisions.
Gedion Mengistu Dejen
wiley   +1 more source

Comparing Partition and Mixture Models with Akaike Information Criteria. [PDF]

Syst Biol
Susko E, Lanfear R, Roger AJ.
europepmc   +1 more source

Intranasal diamorphine population pharmacokinetics modeling and simulation in pediatric breakthrough pain

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 435-447, March 2025.
Abstract Intranasal diamorphine (IND), approved for managing breakthrough pain in the UK, has been identified as an acceptable alternative offering effective, expedient, and less traumatic analgesia for children. However, the current dose regimen in pediatric populations relies on clinical expertise while the pharmacokinetics properties are poorly ...
Lianjin Cai, Jingchen Zhai, Beihong Ji, Fengyang Han, Taoyu Niu, Luxuan Wang, Junmei Wang   +6 more
wiley   +1 more source

Robust Estimation of Polyserial Correlation Coefficients: A Density Power Divergence Approach. [PDF]

Psychometrika
Welz M.
europepmc   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source

A review and evaluation of doubly robust approaches for estimating average treatment effects. [PDF]

Behav Res Methods
Zhang J, Lüdtke O, Robitzsch A.
europepmc   +1 more source

Advancing pharmacometrics in Africa—Transition from capacity development toward job creation

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 407-419, March 2025.
Abstract Trained pharmacometricians remain scarce in Africa due to limited training opportunities, lack of a pharmaceutical product development ecosystem, and emigration to high‐income countries. The Applied Pharmacometrics Training (APT) fellowship program was established to address these gaps and specifically foster job creation for talent retention.
Goonaseelan (Colin) Pillai, Samer Mouksassi, Innocent G. Asiimwe, Craig R. Rayner, Steven Kern, Phumla Sinxadi, Paolo Denti, Eric Decloedt, Catriona Waitt, Bernhards R. Ogutu, Rik de Greef   +10 more
wiley   +1 more source

A Comparison of Testing Procedures for Detecting Short- and Long-Term Effects of Biomarkers for Cancer Screening. [PDF]

Stat Med
Roy S, Albert PS, Roy A, Liu D.
europepmc   +1 more source